{"id":237282,"date":"2026-09-09T12:21:17","date_gmt":"2026-09-09T06:51:17","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=237282"},"modified":"2026-09-09T12:21:17","modified_gmt":"2026-09-09T06:51:17","slug":"is-bafna-pharmaceuticals-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-bafna-pharmaceuticals-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Bafna Pharmaceuticals a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Bafna Pharmaceuticals share price around Rs 302. 5.3% below 52-week high of Rs 318. Q1 FY27 revenue Rs 27 crore, down 23.2% YoY. PAT Rs 0.08 crore, down 97.6%. PE 94x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Bafna Pharmaceuticals’ Q1 FY27 results were mixed, with revenue at Rs 27 crore but PAT falling 98% to Rs 0.08 crore. The Bafna Pharmaceuticals share price near Rs 302 has not escaped this pressure, and the profit decline is the key data point investors should weigh before deciding whether Bafna Pharmaceuticals is a good buy right now.<\/p>\n<\/p><\/div>\n

The Bafna Pharmaceuticals share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Bafna Pharmaceuticals is a Chennai-based manufacturer of pharmaceutical formulations, with its stock on a sharp recent rally, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 27 crore, down 23.2% year on year, while profit after tax came in at Rs 0.08 crore, down 97.6% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Bafna Pharmaceuticals share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Bafna Pharmaceuticals share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n